|
CN103608032A
|
|
Method for suppressing an immune response
|
|
WO2008007941A1
|
|
Gainac specific binding molecules and uses thereof
|
|
WO03066095A2
|
|
MODULATING TOLERANCE BY MODULATING FcϜRIIB RECEPTOR SIGNALLING
|
|
AU2002358102A1
|
|
Use of 7-monohydroxyethylrutoside for the treatment of haematological disorders, particurlarly beta-thalassemia
|
|
EP1417965A1
|
|
C-type lectin binding molecules, identification and uses thereof
|
|
EP1327688A1
|
|
Adenoviruses with enhanced lytic potency
|
|
WO02089819A1
|
|
Glycoconjugates and uses thereof
|
|
AU7561300A
|
|
Novel flavonoids
|
|
EP1167533A1
|
|
Methods and means for the complementation of viral protein expression in stable cell lines
|
|
EP1552831A1
|
|
Use of riluzole for treating multiple sclerosis
|
|
US6872739B1
|
|
Use of riluzole for the treatment of multiple sclerosis
|
|
NL8902544A
|
|
1,10-phenanthroline derivatives.
|
|
NL8800756A
|
|
Genetically manufactured plant cells and plants and useable recombinant dna.
|
|
NL8601585A
|
|
N- (2-SUBSTITUTED ALKYL) -N-imidazol-4-YL ALKYL guanidine.
|
|
NL8503413A
|
|
Preparations for the prevention of diarrhee.
|
